Author
Listed:
- Alex J. Cornish
(Institute of Cancer Research)
- Andreas J. Gruber
(University of Konstanz
University of Manchester)
- Ben Kinnersley
(Institute of Cancer Research
University College London Cancer Institute)
- Daniel Chubb
(Institute of Cancer Research)
- Anna Frangou
(University of Oxford
Max Planck Institute for Molecular Cell Biology and Genetics)
- Giulio Caravagna
(University of Trieste
Institute of Cancer Research)
- Boris Noyvert
(University of Birmingham)
- Eszter Lakatos
(Institute of Cancer Research
Chalmers University of Technology)
- Henry M. Wood
(University of Leeds)
- Steve Thorn
(University of Oxford)
- Richard Culliford
(Institute of Cancer Research)
- Claudia Arnedo-Pac
(The Barcelona Institute of Science and Technology
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
Institució Catalana de Recerca i Estudis Avançats (ICREA))
- Jacob Househam
(Institute of Cancer Research)
- William Cross
(Institute of Cancer Research
UCL Cancer Institute)
- Amit Sud
(Institute of Cancer Research)
- Philip Law
(Institute of Cancer Research)
- Maire Ni Leathlobhair
(Trinity College)
- Aliah Hawari
(University of Manchester)
- Connor Woolley
(University of Oxford)
- Kitty Sherwood
(University of Oxford
University of Edinburgh)
- Nathalie Feeley
(University of Oxford
University of Edinburgh)
- Güler Gül
(University of Edinburgh)
- Juan Fernandez-Tajes
(University of Oxford)
- Luis Zapata
(Institute of Cancer Research)
- Ludmil B. Alexandrov
(UC San Diego
UC San Diego
UC San Diego)
- Nirupa Murugaesu
(Queen Mary University of London)
- Alona Sosinsky
(Queen Mary University of London)
- Jonathan Mitchell
(Queen Mary University of London)
- Nuria Lopez-Bigas
(The Barcelona Institute of Science and Technology
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
Institució Catalana de Recerca i Estudis Avançats (ICREA))
- Philip Quirke
(University of Leeds)
- David N. Church
(University of Oxford
Oxford University Hospitals NHS Foundation Trust)
- Ian P. M. Tomlinson
(University of Oxford)
- Andrea Sottoriva
(Institute of Cancer Research
Human Technopole)
- Trevor A. Graham
(Institute of Cancer Research)
- David C. Wedge
(University of Manchester)
- Richard S. Houlston
(Institute of Cancer Research)
Abstract
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2–9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichia colipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11–13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care.
Suggested Citation
Alex J. Cornish & Andreas J. Gruber & Ben Kinnersley & Daniel Chubb & Anna Frangou & Giulio Caravagna & Boris Noyvert & Eszter Lakatos & Henry M. Wood & Steve Thorn & Richard Culliford & Claudia Arned, 2024.
"The genomic landscape of 2,023 colorectal cancers,"
Nature, Nature, vol. 633(8028), pages 127-136, September.
Handle:
RePEc:nat:nature:v:633:y:2024:i:8028:d:10.1038_s41586-024-07747-9
DOI: 10.1038/s41586-024-07747-9
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:633:y:2024:i:8028:d:10.1038_s41586-024-07747-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.